Alterity Therapeutics Limited (NASDAQ:ATHE) Short Interest Down 45.9% in November

Alterity Therapeutics Limited (NASDAQ:ATHE) saw a significant decline in short interest during the month of November. As of November 30th, there was short interest totalling 2,000 shares, a decline of 45.9% from the November 15th total of 3,700 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 42,700 shares, the days-to-cover ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Maxim Group started coverage on shares of Alterity Therapeutics in a research note on Thursday. They issued a “buy” rating and a $8.00 price objective on the stock.

Alterity Therapeutics Stock Up 8.1 %

ATHE traded up $0.18 during trading on Friday, reaching $2.40. 44,033 shares of the company’s stock were exchanged, compared to its average volume of 50,530. The business has a 50 day moving average price of $1.36 and a 200 day moving average price of $1.51. Alterity Therapeutics has a fifty-two week low of $1.00 and a fifty-two week high of $3.25.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.